Department of Emergency Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Department of Cardiology, Seoul National University Bundang Hospital, Seongnam, Korea.
J Korean Med Sci. 2022 Mar 14;37(10):e81. doi: 10.3346/jkms.2022.37.e81.
Rapid revascularization is the key to better patient outcomes in ST-elevation myocardial infarction (STEMI). Direct activation of cardiac catheterization laboratory (CCL) using artificial intelligence (AI) interpretation of initial electrocardiography (ECG) might help reduce door-to-balloon (D2B) time. To prove that this approach is feasible and beneficial, we assessed the non-inferiority of such a process over conventional evaluation and estimated its clinical benefits, including a reduction in D2B time, medical cost, and 1-year mortality.
This is a single-center retrospective study of emergency department (ED) patients suspected of having STEMI from January 2021 to June 2021. Quantitative ECG (QCG™), a comprehensive cardiovascular evaluation system, was used for screening. The non-inferiority of the AI-driven CCL activation over joint clinical evaluation by emergency physicians and cardiologists was tested using a 5% non-inferiority margin.
Eighty patients (STEMI, 54 patients [67.5%]) were analyzed. The area under the curve of QCG score was 0.947. Binned at 50 (binary QCG), the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were 98.1% (95% confidence interval [CI], 94.6%, 100.0%), 76.9% (95% CI, 60.7%, 93.1%), 89.8% (95% CI, 82.1%, 97.5%) and 95.2% (95% CI, 86.1%, 100.0%), respectively. The difference in sensitivity and specificity between binary QCG and the joint clinical decision was 3.7% (95% CI, -3.5%, 10.9%) and 19.2% (95% CI, -4.7%, 43.1%), respectively, confirming the non-inferiority. The estimated median reduction in D2B time, evaluation cost, and the relative risk of 1-year mortality were 11.0 minutes (interquartile range [IQR], 7.3-20.0 minutes), 26,902.2 KRW (22.78 USD) per STEMI patient, and 12.39% (IQR, 7.51-22.54%), respectively.
AI-assisted CCL activation using initial ECG is feasible. If such a policy is implemented, it would be reasonable to expect some reduction in D2B time, medical cost, and 1-year mortality.
ST 段抬高型心肌梗死(STEMI)患者的关键是实现快速再灌注。利用人工智能(AI)对初始心电图(ECG)的解读直接激活心脏导管室(CCL),可能有助于缩短门球时间(D2B)。为了证明这种方法的可行性和益处,我们评估了这种方法与传统评估相比的非劣效性,并估计了其临床益处,包括缩短 D2B 时间、降低医疗成本和降低 1 年死亡率。
这是一项单中心回顾性研究,纳入 2021 年 1 月至 6 月期间急诊科疑似 STEMI 的患者。使用综合心血管评估系统——定量心电图(QCG)进行筛查。通过 5%的非劣效性边际来测试 AI 驱动的 CCL 激活与急诊医师和心脏病专家联合临床评估的非劣效性。
共分析了 80 例患者(STEMI 患者 54 例[67.5%])。QCG 评分的曲线下面积为 0.947。以 50 为界(二进制 QCG),其灵敏度、特异度、阳性预测值(PPV)和阴性预测值(NPV)分别为 98.1%(95%置信区间[CI],94.6%,100.0%)、76.9%(95% CI,60.7%,93.1%)、89.8%(95% CI,82.1%,97.5%)和 95.2%(95% CI,86.1%,100.0%)。二进制 QCG 和联合临床决策之间的敏感性和特异性差异分别为 3.7%(95% CI,-3.5%,10.9%)和 19.2%(95% CI,-4.7%,43.1%),证实了非劣效性。估计 D2B 时间、评估成本和 1 年死亡率的中位数降低分别为 11.0 分钟(四分位距[IQR],7.3-20.0 分钟)、每位 STEMI 患者 26902.2 韩元(22.78 美元)和 12.39%(IQR,7.51-22.54%)。
使用初始 ECG 的 AI 辅助 CCL 激活是可行的。如果实施这样的政策,有望合理缩短 D2B 时间、降低医疗成本和降低 1 年死亡率。